13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03995810
(ClinicalTrials.gov)
June 15, 201918/6/2019Oral Carnosine for Neuromuscular Performance in Multiple SclerosisOral Carnosine for Neuromuscular Performance, Brain Biomarkers of Carnosine Metabolism and Health-related Quality of Life in Multiple SclerosisMultiple SclerosisDietary Supplement: Carnosine, capsulle, 2 g/day, 8 weeksUniversity of Novi Sad, Faculty of Sport and Physical EducationCarnoMedCompleted18 Years65 YearsAll3N/ASerbia
2NCT03418376
(ClinicalTrials.gov)
February 1, 20179/1/2018Carnosine Loading and Periodized Training in MS and HCThe Impact of Carnosine Loading and Rehabilitation Therapy on Exercise Capacity in Multiple Sclerosis.Multiple Sclerosis;Exercise Therapy;Dietary SupplementDietary Supplement: Beta-alanine supplementation;Other: Exercise interventionHasselt UniversityNULLCompleted18 Years75 YearsAll45N/ABelgium